Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Results of the Phase II GeparNuevo trial

Evandro de Azambuja, MD, PhD, L’Universite Libre de Bruxelles, Brussels, Belgium, discusses the results of the GeparNuevo trial (NCT02685059), which looks at taxane-anthracycline chemotherapy with and without addition of durvalumab immunotherapy for triple negative breast cancer. After a follow up of 43 months, it was found that patients who were treated with chemotherapy/immunotherapy had a better invasive disease-free survival (IDFS), distant disease-free survival (DDFS) and overall survival. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.